Abstract:Key PointsMost human cancers exhibit a high degree of intratumour heterogeneity that arises from heritable and stochastic genetic and epigenetic changes, as well as environmental variations within the tumour. Heterogeneous subpopulations that exist within close proximity and compete for limited resources can engage in complex interactions that affect tumorigenesis, disease progression and therapeutic outcomes.Phenotypic changes that arise from subclonal interactions in heterogeneous tumours were observed by cancer biologists very early on. However, as studies mostly focused on cell-autonomous oncogenes and tumour suppressors, investigations into clonal interactions went under the radar for almost three decades. With the increasing recognition of intratumour heterogeneity fuelled by advances in technology, dissecting the mechanistic basis of clonal interactions is now gaining more attention.In addition to the more traditional models that explore clonal interactions strictly from the competitive angle, newer studies are investigating cooperative interactions among subclones that could give rise to novel characteristics and that potentially increase the growth and progression of the tumour.In the absence of proper tools to directly study clonal interactions in patient samples, studies in D. melanogaster, rodents and xenograft systems (using both established cell lines and patient-derived cells) are providing us with mechanistic insights into interclonal crosstalk.Theoretical and mathematical modelling are being used to simulate clonal dynamics under variable circumstances. Although currently far from perfect, these in silico cancer models have already been useful for the design of optimized cancer therapies for the more effective eradication of tumours.Cooperation can be metabolically costly but evolution and survival are more efficient, especially in a changing environment, when diversity and heterogeneity are high. Insights from patient tumours have revealed the presence of multiple independent neoplastic driver subclones that could re-establish tumour heterogeneity after therapy and lead to disease relapse. Furthermore, there is increasing evidence of transient clonal cooperation between neoplastic and benign subclones, which can also lead to tumour recurrence.In order to tackle the ever-evolving populations of tumour cells more effectively and to devise more lasting cures in patients, we must use ecological approaches that take advantage of cooperative tumour-promoting interactions and strategically eliminate them instead of targeting each individual subpopulation.

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Genetic and non-genetic clonal diversity in cancer evolution

Clonal Heterogeneity and Tumor Evolution in Liver Cancer: the Cutting Edge and the Future

Cancer: Evolution Within a Lifetime

Structure of Intratumor Heterogeneity: Is Cancer Hedging Its Bets?

Tumour heterogeneity and resistance to cancer therapies

Cellular Heterogeneity and Molecular Evolution in Cancer

Clinical implications of intratumor heterogeneity: challenges and opportunities

A population genetics perspective on the determinants of intra-tumor heterogeneity

Epigenomic heterogeneity as a source of tumour evolution

Tumorigenesis: it takes a village

Evolution of phenotypic plasticity leads to tumor heterogeneity with implications for therapy

Effective Sub-clonal Cancer Representation to Predict Tumor Evolution

Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB.

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Evolution of intratumoral phenotypic heterogeneity: the role of trait inheritance

Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution

Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression

Big Bang Tumor Growth and Clonal Evolution

Intratumoral heterogeneity and clonal evolution in liver cancer

Molecular heterogeneity in breast cancer: State of the science and implications for patient care